



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville MD 20857

3 2 3 9 '00 MAR -8 AIO :37

MAR 7 2000

SP 99P-5331/CP 1

Hugh H. Johnston, M.D.
CEO and Medical Director
PharmX, Inc.
75 Market Street, Suite 305
Portland, Maine 04101

Dear Dr. Johnston:

We refer to your suitability petition filed December 13, 1999, in which you requested permission to submit an abbreviated new animal drug application (ANADA) for a generic product with a dosage form that differs from that of an approved new animal drug. The proposed pioneer product is Phoenix Scientific's PHENYLBUTE™ (phenylbutazone tablets) which is intended for use in horses (NADA 91-818).

Your proposed product differs from the pioneer product in dosage form and therefore delivery method. The pioneer product is a tablet, whereas your proposed product is a dose-unit packet of pellets administered in a small amount of feed or alternatively by dissolution in water with administration orally via syringe. The dosage of active ingredient per pound of body weight will be the same.

Change in dosage form is one of the five variances in the pioneer product which can be considered through a suitability petition under section 512(n)(3) of the Federal Food, Drug, and Cosmetic Act, as amended. We are required to approve the petition unless we determine that investigations must be conducted to establish the safety and effectiveness of the proposed generic product.

Your suitability petition is approved. Approval of the suitability petition does not alter the requirements for approval of the ANADA, nor assure approval of the ANADA.

In addition to the study to show bioequivalence between the pioneer and generic products, we may require you to conduct a palatability study with the generic product. Palatability is not directly related to effectiveness. Palatability studies may be required in an ANADA with regard to the change in dosage form under section 512(n)(1)(D) of the FFDCA. We recommend that you submit protocols for our evaluation before initiating any studies.

We will conduct a definitive labeling review when the ANADA for the proposed generic product is submitted to the Center. The generic labeling should be a verbatim copy of the approved labeling for the pioneer, with certain allowable differences, such as directions for administration of the dose-unit packet of pellets versus the tablet.


99P-5331

PAVI

SP 99P-5331/CP 1
Page 2

You may contact Dr. Lonnie W. Luther, Chief, Generic Animal Drug and Quality Assurance Staff, (301) 827-0209, for any questions on the specific requirements for the ANADA submission.

Sincerely yours,

A handwritten signature in black ink that reads "Claire M. Lathers". The signature is written in a cursive style with a large, looping initial "C".

Claire M. Lathers, Ph.D., F.C.P.
Director
Office of New Animal Drug Evaluation
Center for Veterinary Medicine

PAGE 1

DECEMBER 14, 1999

DOCKET NUMBER: 99P-5331

TITLE: ANADA suitability for Palabute (phenylbutazone) Pellets
ACTION OFFICE: HFV-102

FAP/LAP/GRASP Number:

ITEM CODE	RECEIVED MM DD YY	FILED MM DD YY	P C	SUBMITTER	FR DATE	FR PAGE	COM/OBJ MM DD YY	VOL	MISCELLANEOUS
CP1	12/13/99	12/13/99	C	PharmX Inc Signature: Hugh H Johnston MD					1 ACK 12/14/99
ACK1	12/14/99	12/14/99	E	HFA-305 Signature: Jennie Butler					1

99P 5331

rec'd DEC 17 1999
TO WORK DEC 17 1999

MEMO

DEPARTMENT OF HEALTH AND HUMAN SERVICES
PUBLIC HEALTH SERVICE
FOOD AND DRUG ADMINISTRATION
CENTER FOR VETERINARY MEDICINE

3 2 3 8 '00 MAR -8 AIO 37

DATE: 3/7/00

FROM: Animal Scientist
Quality Assurance Support Staff, HFV-102


SUBJECT: Suitability Petition Response for Display.

TO: Lyle Jaffe, HFA-305, 5630 Fishers Lane, rm. 1061, Rockville, MD
Dockets Management Branch, 301 827-6860 (V)

The attachment is the Center for Veterinary Medicine's Letter related to Suitability Petition **SP 99P-5331CP 1**, PharmX filed as a **Suitability Petition**. We are forwarding a copy for public display with the petition.

If you have any questions, please call me at 827-0211, or FAX 594-2297.

Thank you.



Sam Hansard, Ph.D.

Attachment

Samuel Hansard, Ph.D.
FDA/CVM/ONADE/QASS/HFV-102
7500 Standish Place MPN II 384
Rockville, MD 20855
(301) 827-0211
(301) 594-2297 fax
shansard@cvm.fda.gov